KNTE
NASDAQKinnate Biopharma Inc.
Latest news
25 items- SECSEC Form 15-12G filed by Kinnate Biopharma Inc.15-12G - Kinnate Biopharma Inc. (0001797768) (Filer)
- INSIDERTananbaum James B. returned 13,718,311 shares to the company (SEC Form 4)4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- INSIDERKrishnamohan Neha returned 64,087 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- INSIDERSEC Form 4 filed by Mitchell Dean J4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- INSIDERFarzan Nima returned 2,186 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- INSIDERSEC Form 4 filed by Epperly Melissa B,4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- INSIDERSEC Form 4 filed by Smaldone Alsup Laurie4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- INSIDERFlaherty Keith T. returned 66,377 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- INSIDERSEC Form 4 filed by Sabzevari Helen4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- INSIDERSEC Form 4 filed by Rome Michael E4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- INSIDERMeltz Mark A returned 27,578 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- INSIDERSEC Form 4 filed by Desimone Jill4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- INSIDERGordon Carl L returned 8,009,729 shares to the company (SEC Form 4)4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- INSIDEROrbimed Advisors Llc returned 8,009,729 shares to the company (SEC Form 4)4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Kinnate Biopharma Inc. (Amendment)SC 13D/A - Kinnate Biopharma Inc. (0001797768) (Subject)
- INSIDERForesite Capital Management Iv, Llc returned 13,718,311 shares to the company (SEC Form 4)4 - Kinnate Biopharma Inc. (0001797768) (Issuer)
- SECSEC Form S-8 POS filed by Kinnate Biopharma Inc.S-8 POS - Kinnate Biopharma Inc. (0001797768) (Filer)
- SECSEC Form S-8 POS filed by Kinnate Biopharma Inc.S-8 POS - Kinnate Biopharma Inc. (0001797768) (Filer)
- SECSEC Form S-8 POS filed by Kinnate Biopharma Inc.S-8 POS - Kinnate Biopharma Inc. (0001797768) (Filer)
- SECSEC Form POSASR filed by Kinnate Biopharma Inc.POSASR - Kinnate Biopharma Inc. (0001797768) (Filer)
- SECKinnate Biopharma Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant8-K - Kinnate Biopharma Inc. (0001797768) (Filer)
- SECSEC Form SC 14D9/A filed by Kinnate Biopharma Inc. (Amendment)SC 14D9/A - Kinnate Biopharma Inc. (0001797768) (Subject)
- SECSEC Form 25-NSE filed by Kinnate Biopharma Inc.25-NSE - Kinnate Biopharma Inc. (0001797768) (Subject)
- SECSEC Form SC TO-T/A filed by Kinnate Biopharma Inc. (Amendment)SC TO-T/A - Kinnate Biopharma Inc. (0001797768) (Subject)
- PRXOMA Corporation Announces Closing of Tender OfferEMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) common stock for a price per share of $2.5879 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Price") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate p
KNTE FAQ
7 questionsWhat does Kinnate Biopharma Inc. do?
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. The company was...Where does KNTE stock trade?
Kinnate Biopharma Inc. (KNTE) is listed on NASDAQ.What sector and industry is KNTE in?
Kinnate Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Kinnate Biopharma Inc. go public?
Kinnate Biopharma Inc. (KNTE) completed its IPO in 2020.What are analysts saying about KNTE?
Kinnate Biopharma Inc. has had 5 recent analyst actions on file. The most recent action was from Stifel: Hold with a $1100.00 price target on 2022-11-17. Recent price targets range from $1100.00 to $4600.00.What companies are similar to KNTE?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare KNTE side-by-side with any of them on Quantisnow.How can I track KNTE on Quantisnow?
Quantisnow aggregates Kinnate Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KNTE to receive live email and push alerts on every new disclosure.